Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin Suspension in Pediatric NDO (MONKEY)
NCT01565694Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2012
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
A Phase 3 trial of solifenacin in neurogenic detrusor overactivity (NDO), sponsored by Astellas Pharma. Started Aug 2012; status: completed.
02
Drugs
solifenacin
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT01565694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01565694.